HC Wainwright Analysts Increase Earnings Estimates for ACAD

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) – Stock analysts at HC Wainwright raised their Q3 2026 EPS estimates for ACADIA Pharmaceuticals in a research report issued on Wednesday, August 5th. HC Wainwright analyst A. Ghosh now forecasts that the biopharmaceutical company will post earnings per share of $0.15 for the quarter, up from their previous estimate of $0.13. HC Wainwright currently has a “Hold” rating on the stock. The consensus estimate for ACADIA Pharmaceuticals’ current full-year earnings is $0.39 per share. HC Wainwright also issued estimates for ACADIA Pharmaceuticals’ Q4 2026 earnings at $0.20 EPS and FY2027 earnings at $1.89 EPS.

A number of other brokerages have also recently issued reports on ACAD. BMO Capital Markets upped their target price on shares of ACADIA Pharmaceuticals from $34.00 to $36.00 and gave the company an “outperform” rating in a report on Tuesday, July 21st. Stifel Nicolaus raised their price objective on ACADIA Pharmaceuticals from $24.00 to $25.00 and gave the company a “hold” rating in a research report on Tuesday, July 21st. Citigroup reissued a “market outperform” rating on shares of ACADIA Pharmaceuticals in a report on Wednesday. Oppenheimer increased their price objective on shares of ACADIA Pharmaceuticals from $23.00 to $25.00 and gave the company a “market perform” rating in a research report on Wednesday. Finally, Citizens Jmp lifted their target price on shares of ACADIA Pharmaceuticals from $35.00 to $36.00 and gave the stock a “market outperform” rating in a report on Wednesday. Thirteen investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $32.53.

ACADIA Pharmaceuticals Price Performance

Shares of ACAD opened at $28.80 on Thursday. The company has a market cap of $4.93 billion, a PE ratio of 12.97, a price-to-earnings-growth ratio of 18.82 and a beta of 0.81. The firm has a 50-day moving average of $24.10 and a 200-day moving average of $23.22. ACADIA Pharmaceuticals has a one year low of $19.69 and a one year high of $29.17.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last posted its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.18 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.07 by $0.11. The firm had revenue of $308.00 million for the quarter, compared to analyst estimates of $296.55 million. ACADIA Pharmaceuticals had a net margin of 33.42% and a return on equity of 9.38%. The company’s quarterly revenue was up 16.4% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.16 earnings per share.

Hedge Funds Weigh In On ACADIA Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ACAD. Norges Bank acquired a new position in shares of ACADIA Pharmaceuticals in the 4th quarter valued at approximately $40,266,000. Millennium Management LLC boosted its position in shares of ACADIA Pharmaceuticals by 2,052.1% during the 3rd quarter. Millennium Management LLC now owns 1,483,235 shares of the biopharmaceutical company’s stock worth $31,652,000 after acquiring an additional 1,414,315 shares in the last quarter. Arrowstreet Capital Limited Partnership boosted its position in shares of ACADIA Pharmaceuticals by 390.1% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 1,648,864 shares of the biopharmaceutical company’s stock worth $35,187,000 after acquiring an additional 1,312,426 shares in the last quarter. First Trust Advisors LP increased its stake in ACADIA Pharmaceuticals by 47.3% in the first quarter. First Trust Advisors LP now owns 3,343,868 shares of the biopharmaceutical company’s stock valued at $74,435,000 after acquiring an additional 1,073,834 shares during the last quarter. Finally, Logos Global Management LP bought a new position in ACADIA Pharmaceuticals in the fourth quarter valued at approximately $22,704,000. 96.71% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, insider James Kihara sold 5,401 shares of the business’s stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $21.18, for a total value of $114,393.18. Following the completion of the sale, the insider directly owned 24,509 shares in the company, valued at approximately $519,100.62. The trade was a 18.06% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Elizabeth H.Z. Thompson sold 16,558 shares of the stock in a transaction that occurred on Thursday, July 30th. The stock was sold at an average price of $26.13, for a total value of $432,660.54. Following the sale, the executive vice president directly owned 18,994 shares in the company, valued at $496,313.22. This represents a 46.57% decrease in their position. The SEC filing for this sale provides additional information. Corporate insiders own 26.20% of the company’s stock.

Key ACADIA Pharmaceuticals News

Here are the key news stories impacting ACADIA Pharmaceuticals this week:

• Positive Sentiment: Second-quarter results exceeded expectations. ACADIA reported adjusted EPS of $0.18, ahead of the $0.06 consensus estimate and above $0.16 a year earlier. Revenue rose 16.4% year over year to $308 million, exceeding expectations of approximately $295.5 million. Acadia Pharmaceuticals Q2 Earnings and Revenues Beat Estimates
• Positive Sentiment: Commercial momentum supported the beat. Strong sales of DAYBUE and NUPLAZID, along with continued patient demand and DAYBUE’s STIX uptake, drove the performance. Management described execution across both products as strong. Acadia Pharmaceuticals Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Full-year 2026 revenue guidance was raised. ACADIA now expects revenue of $1.2 billion to $1.3 billion, compared with a consensus estimate near $1.2 billion. The improved outlook reinforces expectations for continued growth from its marketed products. ACAD Q2 Earnings and Revenues Beat, 2026 View Raised on Product Sales
• Positive Sentiment: Citizens JMP increased its price target to $36 from $35 and maintained a “market outperform” rating, implying further upside based on the cited $28.80 reference price. Citizens JMP Raises ACADIA Price Target

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders. Established in 1993 and headquartered in San Diego, California, ACADIA’s research centers concentrate on conditions with significant unmet medical needs, including Parkinson’s disease psychosis, Alzheimer’s disease psychosis, and schizophrenia. The company utilizes a range of scientific platforms, including selective receptor modulation and precision-targeted compounds, to advance its portfolio of small-molecule therapeutics.

The company’s flagship product, NUPLAZID® (pimavanserin), received U.S.